The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
Edward Barnes, MD, MPH, discussed practical implications to consider when positioning medications in the management of IBD during his presentation at the Advances in Inflammatory Bowel Diseases Regional in...
Stephen Hanauer, MD, from Northwestern Medicine, discussed key windows of opportunity for effective management of Crohn disease during his presentation at the Advances in Inflammatory Bowel Diseases...
The guideline developed by the American Society for Gastrointestinal Endoscopy addressed 5 clinical questions on when and how to screen and survey individuals with Barrett esophagus.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
By studying a nationwide cohort of more than 16,600 individuals with viral hepatitis, researchers determined whether the use of lipophilic and hydrophilic statins can impact hepatocellular carcinoma...
Researchers evaluated data on more than 6600 children to determine whether the amount of gluten consumed during the first 5 years of life influenced the development of celiac disease autoimmunity and celiac...
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
Researchers evaluated data on more than 17,000 individuals with an autoimmune disease who received treatment with an anti-tumor necrosis factor α agent to determine the risk of developing new inflammatory...
In the longest vedolizumab continuous treatment study to date, GEMINI LTS provided insight on the long-term safety and efficacy of vedolizumab use in ulcerative colitis and Crohn disease. Final results were...
